Literature DB >> 1697730

Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: Correlation between biochemical and immunohistochemical methods and survival.

J T Chambers1, M L Carcangiu, I M Voynick, P E Schwartz.   

Abstract

One hundred eighty-three patients with endometrial carcinoma had both immunohistochemical and biochemical analysis of estrogen receptor (ER) and progesterone receptor (PR) content of the tumor. Biochemical analysis was done on a homogenate of uterine curettings; immunohistochemical stainings were done on formalin-fixed, paraffin-embedded sections. The biochemical method was scored quantitatively and the immunohistochemical, in a semiquantitative way. There was a significant correlation between the immunohistochemical categories of the malignant component of the tumor and the biochemical levels of receptor content (P = 0.0001). The sensitivity of the immunohistochemical method for the ER content was 78.5% and the specificity was 58.2%. The sensitivity for the PR was 52.5% and the specificity was 92.8%. Changing cut-off levels for positivity of the biochemical analysis changed the sensitivity and specificity. Survival was predicted by the immunohistochemical status of the ER (P = 0.001) and PR (P = 0.01). Similarly, it was predicted by the biochemical receptor status. Multivariate analysis of the immunohistochemical receptor status and the biochemical receptor status showed that the immunohistochemically determined estrogen status was the most significant predictor of survival (P = 0.001). The immunohistochemical analysis of sex steroid receptor status on formalin-fixed, paraffin-embedded tissue is not only possible and practical, but also predicts survival.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697730     DOI: 10.1093/ajcp/94.3.255

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

1.  Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analyses.

Authors:  H C van Doorn; C W Burger; P van der Valk; H M Bonfrèr
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

2.  Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium.

Authors:  Sema Bircan; Arzu Ensari; Sibel Ozturk; Nural Erdogan; Ilkkan Dundar; Firat Ortac
Journal:  Pathol Oncol Res       Date:  2005-03-31       Impact factor: 3.201

3.  Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer.

Authors:  Houshiyar Ghafouri; Bayazid Ghaderi; Sabrieh Amini; Bahram Nikkhoo; Mohammad Abdi; Abdolhakim Hoseini
Journal:  Tumour Biol       Date:  2015-12-23

4.  A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.

Authors:  Linda R Duska; Virginia L Filiaci; Joan L Walker; Laura L Holman; Emily K Hill; Richard G Moore; Kari L Ring; Michael L Pearl; Carolyn Y Muller; Christina L Kushnir; Heather A Lankes; Megan I Samuelson; Kelley S Carrick; Anand Rajan; William H Rodgers; Elise C Kohn; Richard Piekarz; Kimberly K Leslie
Journal:  Clin Cancer Res       Date:  2021-03-25       Impact factor: 12.531

5.  Association of XRCC1 Trp194 allele with risk of breast cancer, and Ki67 protein status in breast tumor tissues.

Authors:  Chiya Jalali; Bayazid Ghaderi; Sabrieh Amini; Mohammad Abdi; Daem Roshani
Journal:  Saudi Med J       Date:  2016-06       Impact factor: 1.484

6.  The independent, unfavorable prognostic factors endothelin A receptor and chemokine receptor 4 have a close relationship in promoting the motility of nasopharyngeal carcinoma cells via the activation of AKT and MAPK pathways.

Authors:  Dong-Hua Luo; Qiu-Yan Chen; Huai Liu; Li-Hua Xu; Hui-Zhong Zhang; Lu Zhang; Lin-Quan Tang; Hao-Yuan Mo; Pei-Yu Huang; Xiang Guo; Hai-Qiang Mai
Journal:  J Transl Med       Date:  2013-08-29       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.